Therapeutic Efficacy of Ketanserin, a Selective Antagonist of the Serotonin (5-HT2) Receptors, in Primary and Secondary Raynaud's Phenomenon

Meloni, Fortunato; Transi, Maria Grazia; Sciacca, Vincenzo; de Felice, Carlo; Bagarone, Amedeo; Sciacca, Andrea
July 1987
Angiology;Jul1987, Vol. 38 Issue 7, p530
Academic Journal
Fourteen ambulatory and hospitalized patients with primary and secondary Raynaud's phenomenon have been examined before and after a thirty-one-day therapeutic trial. The treatment was conducted in two cycles. The first one lasted ten days, during which placebo was administered. The second cycle lasted three weeks, during which ketanserin, a selective antagonist of 5-hydroxytryptamine (S-HT2) receptors, was administered. The therapeutic effect consisted of the complete healing of digital ulcers in 4 of 5 patients and a considerable decrease in the number, length, and severity of daily attacks. To evaluate the digital blood flow, each patient was submitted to a medical dynamic telethermographic test. This, after the cooling test, demonstrated an average decrease of twenty minutes in the time necessary to reestablish basal thermal conditions (T′) at the end of an adequate period of therapy using optimal doses of the drug. The authors affirm that orally administered ketanserin has a beneficial effect and can be well tolerated in subjects with Raynaud's phenomenon.


Related Articles

  • New Prospects for the Treatment of Raynaud's Phenomenon Using A Serotoninergic S2 Receptor Antagonist (Ketanserin) and Stable Derivatives of Prostacyclin. Pola, Paolo; Tondi, Paolo; Serricchio, Michele; Favuzzi, Angela; Gerardino, Laura // Angiology;Feb1993, Vol. 44 Issue 2, p123 

    The authors propose a promising new therapy for the treatment of Raynaud's phenomenon, with parenteral prostacyclin (carbaprostacycline) and a serotonergic S2-receptor antagonist (ketanserin) given orally. They studied 31 patients, 22 treated with ketanserin and carbaprostacycline, 9 with...

  • Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Roald, Ole Kristian; Seem, Egil // British Medical Journal (Clinical Research Edition);9/8/1984, Vol. 289 Issue 6445, p577 

    Evaluates the effectiveness of ketanserin in treating Raynaud's phenomenon in patients with connective tissue disorders. Assessment of digital blood flow; Role of serotonin in the development of peripheral vasoconstrictive diseases; Use of laser Doppler flowmetry to determine the...

  • Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin. Stranden, E.; Roald, O.K.; Krohg, K. // British Medical Journal (Clinical Research Edition);10/16/1982, Vol. 285 Issue 6348, p1069 

    Investigates the efficacy of 5-HT[sub 2]-receptor antagonist ketanserin for treatment of Raynaud's phenomenon. Effect of the ketanserin on blood flow; Increase in digital blood flow and skin temperature; Characterization of the disease.

  • Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. Onofrj, Marco; Paci, Cristina; D'Andreamatteo, Giordano; Toma, Lucia // Journal of Neurology;Jun2000, Vol. 247 Issue 6, p443 

    We selected four patients with severe Gilles de la Tourette syndrome, high frequency of tics (two to ten per minute), vocalizations, and lack of comorbidity. These patients (aged 19–40 years) underwent a 52-week double-blind cross-over study with olanzapine (5 and 10 mg daily) vs....

  • Ketanserin in the treatment of traumatic vasospastic disease. Larsen, Vagn Hojkjaer; Fabricius, Jorgen; Nielsen, Gunner; Hansen, Klaus Stagis // British Medical Journal (Clinical Research Edition);9/13/1986, Vol. 293 Issue 6548, p650 

    Assesses Ketanserin administration for the treatment of traumatic vasospastic disease. Mechanism of action of Ketanserin; Enhancement of digital circulation; Adverse effects in the use of Ketanserin.

  • Placebo-Controlled Trial of Ketanserin in the Treatment of Intermittent Claudication. Cameron, H. A.; Waller, P. C.; Ramsay, L. E. // Angiology;Jul1987, Vol. 38 Issue 7, p549 

    The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months'...

  • 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray mediate the antipanic-like effect induced by the stimulation of serotonergic neurons in the dorsal raphe nucleus. Pobbe, Roger L. H.; Zangrossi Jr., Hélio // Psychopharmacology;Dec2005, Vol. 183 Issue 3, p314 

    Rationale: It has been proposed that the serotonergic pathway that connects the dorsal raphe nucleus (DRN) to the dorsal periaqueductal gray (DPAG) is implicated in the regulation of escape, a behavior that has been related to panic. Objectives: We further evaluated this hypothesis by...

  • Effect of 5-HT2 Receptor Blockade on Cadmium-Induced Acute Toxicity. Konstantinos Tzirogiannis; Maria Demonakou; George Papadimas; Spyridon Skaltsas; Georgia Manta; Kalliopi Kourentzi; Katerina Alexandropoulou; Rosa Hereti; Michael Mykoniatis; Georgios Panoutsopoulos // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2351 

    Abstract  The protective effect of 5-HT2 receptor blockade with ketanserin or ritanserin against cadmium liver injury was investigated. Male Wistar rats were injected intraperitoneally with a sublethal dose of cadmium (3.5 mg/kg body weight). Rats were treated with normal...

  • Does serotonin relax the rat anococcygeus muscle via 5-HT7 receptors? Emre, Selda; Erdem, Ş. Remzi; Tuncer, Meral // Naunyn-Schmiedeberg's Archives of Pharmacology;Aug2000, Vol. 362 Issue 2, p96 

    The mechanisms of serotonin (5-HT)-induced contraction and relaxation were studied in the rat anococcygeus muscle. In the presence of prazosin (1 nM) and ketanserin (10 nM), concentration/response curves to 5-HT were shifted to the right and the maximum effects were not affected (pKB values...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics